News
Lopimune - called Kaletra (Ritonavir/Lopinavir - chemical Name)
Effect of Lopinavir/ritonavir (Kaletra) Monotherapy on Symptoms and Quality of Life
However, other therapeutic strategies could be beneficial given the long-term toxicities and quality of life issues associated with taking multiple antiretroviral drugs for many years.
Time to Virological Failure with Boosted Atazanavir (Reyataz) or...
Time to Virological Failure with Boosted Atazanavir or Lopinavir/ritonavir Is Not Affected by Use of H2 Receptor Blockers Antiretroviral drugs have the potential to interact with many other types of medication, ...
No Increased Risk of Birth Defects with Prenatal Lopinavir/ritonavir (Kaletra) Exposure
To address this concern, the Antiretroviral Pregnancy Registry, an international, prospective, exposure registration study, was established in 1989 to collect data on birth outcomes -- primarily birth defects ...
Switching from Other Ritonavir-boosted Protease Inhibitors to Boosted ...
Atazanavir is a potent, well-tolerated, once-daily protease inhibitor that has been extensively studied in both treatment-naive and treatment-experienced patients.
Norvir Tablets Similar to Capsules, Expected in 2009
More Treatment News August 15, 2008 by Tim Horn Abbott Laboratories has developed a tablet version of its protease inhibitor Norvir , typically used in drug regimens to boost blood levels and the effectiveness ...
Uptake of second-line treatment `stagnant` in developing world
The uptake of second-line antiretroviral treatment in developing countries is `stagnant` according to a survey by the World Health Organization presented at last week's XVII International AIDS Conference, ...
Boosted Atazanavir and Lopinavir/ritonavir (Kaletra) Have Similar...
Boosted Atazanavir and Lopinavir/ritonavir Have Similar Efficacy, but Side Effects Differ across Racial/ethnic Groups By Ronald Baker, PhD Race-based differences in efficacy and safety have been reported among ...
Lopinavir/ritonavir (Kaletra) Tablet Dosed Once-Daily or Twice-Daily...
Lopinavir/ritonavir Tablet Dosed Once-Daily or Twice-Daily Confers Similar Clinical Results across Racial/ethnic Lines Non-whites comprise the vast majority of individuals living with HIV disease worldwide.
A Comparison of the Single-dose Bioavailability of a Ritonavir Tablet ...
Ritonavir has been approved by regulatory agencies worldwide and is indicated for use in combination with other antiretroviral agents for the treatment of HIV infection .
GlaxoSmithKline Head-to-Head 96-Week Study Shows EPZICOM(R) is...
GlaxoSmithKline today announced that 96-week data from the HEAT study show that once-daily EPZICOM provides comparable efficacy to once-daily Truvada as a first-line option for the treatment of HIV.